References
- Reed J C. Molecular biology of chronic lymphocytic leukemia: implications for therapy. Semin. Hematol 1998; 35: 3–13
- Hanada M., Delia D., Aiello A., et al. bcl-2 gene hypomethylation and high level expression in B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1820–1828
- Robertson L E, Plunkett W., McConnell K., et al. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 1996; 10: 456–459
- Pepper C., Benüey P., Hoy T. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 1996; 95: 513–517
- Aguilar-Santelises M., Lewin N., et al. Bcl-2, bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int. J. Cancer 1996; 69: 114–119
- Pepper C., Hoy T., Bentley P. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br. J. Cancer 1997; 76: 935–938
- Pepper C., Thomas A., Hoy T., Benüey P. Chlorambucil resistance in B-cell chronic lymphocytic leukaemia is mediated through failed Bax induction and selection of high Bcl-2-expressing subclones. Br. J. Haematol. 1999; 104: 581–588
- Reed J. C., Stein C., Subasinghe C., et al. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res. 1990; 50: 6565–6570
- Kitada S., Miyashita T., Tanaka S., Reed J C. Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. Antisense Res. Dev. 1993; 3: 157–169
- Cotter F. E., Johnson P., Hall P., et al. Antisense oligonucleotides suppress B-cell lymphoma growth in SCID-hu mouse model. Oncogene 1994; 9: 3049–3055
- Webb A., Cunningham D., Cotter F., et al. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997; 349: 1137–1141
- Pepper C., Thomas A., Hoy T., et al. Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 1999; 107: 611–615
- Binet J. L., Auquier A., Dighiro G., et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–206
- Ziegler A., Luedke G H, Fabbro D., et al. Induction of apoptosis in small-cell lung cancer cells by an antisense oligonucleotide targeting the Bcl-2 coding sequence. J. Natl. Cancer Inst. 1997; 89: 1027–1035
- Ferlini C., Di Cesare S., Rainaldi G., et al. Flow cytometric analysis of the early phases of apoptosis by cellular and nuclear techniques. Cytometry 1996; 24: 106–115
- Venues I., Haanen C., Steffens-Nakken H., Reutelingsperger C. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin, V. J. Immunol. Methods 1995; 184: 39–51
- Oltvai Z N, Milliman C L, Korsmeyer S J. bcl-2 heterodimerizes in vitro with a conserved homolog, bax, that accelerates programmed cell death. Cell 1993; 74: 609–619
- Pepper C., Hoy T., Bentley P. Elevated Bcl-2/Bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated with in vivo chemoresistance. Leuk Lymphoma 1998; 28: 355–361